The Concept of CMR
Slides, videos and moreEvaluating CMR
Metabolic Syndrome and Type 2 Diabetes/CVD Risk
Comparison of Screening Tools
- 1Key Points (1 page)
- 2How Are Screening Tools Different? (1 page)
- 3The Insulin Resistance Atherosclerosis Study (1 page)
- 4The Aerobics Center Longitudinal Study (1 page)
- 5The San Antonio Heart Study (1 page)
- 6The Hoorn Study (2 pages)
- 7The DECODE Study (1 page)
- 8The Prospective Epidemiological Study of Myocardial Infarction (1 page)
- 9The Strong Heart Study (1 page)
- 10Additional Evidence (2 pages)
- 11References (1 page)
The Prospective Epidemiological Study of Myocardial Infarction
9 of 13
WHO, NCEP-ATP III, and IDF screening criteria were compared in another very large population-based study of 10,592 men 50 to 59 years of age from France and Belfast (Southern and Northern Europe) followed for 5 years (6). Entitled the prospective epidemiological study of myocardial infarction-étude PRospective de l’Infarctus du MyocardE (PRIME), it involved a nested case-control study cohort that matched 296 cases of coronary heart disease (CHD) to 540 CHD-free controls according to age, recruitment centre, and date. Metabolic syndrome prevalence was 36%, 30%, and 39% in cases and 29%, 23%, and 32% in controls according to WHO, NCEP-ATP III, and IDF clinical criteria, respectively. The corresponding ORs for future CHD were 1.40 (95% CI, 1.01-1.94), 1.46 (95% CI, 1.04-2.04), and 1.41 (95% CI, 1.02-1.95).
9 of 13
